Published in J Urol on August 01, 2001
National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst (2003) 4.81
Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol (2014) 2.45
A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One (2008) 2.09
Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res (2012) 1.71
Locally advanced prostate cancer: a population-based study of treatment patterns. BJU Int (2011) 1.46
Exosomes as biomarker enriched microvesicles: characterization of exosomal proteins derived from a panel of prostate cell lines with distinct AR phenotypes. Mol Cell Proteomics (2012) 1.26
Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1. PLoS One (2013) 1.09
Androgen deprivation therapy for prostate cancer-review of indications in 2010. Curr Oncol (2010) 1.04
Androgen deprivation and cognition in prostate cancer. Br J Cancer (2003) 1.04
GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res (2011) 1.00
Use of androgen deprivation therapy in prostate cancer: indications and prevalence. Asian J Androl (2012) 0.98
Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer. Eur Urol (2013) 0.98
Salvage prostatectomy post-definitive radiation therapy: The Vancouver experience. Can Urol Assoc J (2015) 0.96
Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial. BJU Int (2009) 0.95
Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer. J Clin Pathol (2002) 0.95
Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation. J Clin Endocrinol Metab (2013) 0.93
Comparative study of the impact of 3- versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomy. J Cancer Res Clin Oncol (2007) 0.86
Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer. Cancer (2010) 0.85
Neoadjuvant Therapy for Prostate Cancer: An Oncologist's Perspective. Rev Urol (2003) 0.84
Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor. Urol Oncol (2014) 0.84
Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer. Oncogenesis (2014) 0.84
Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort. Cancer Manag Res (2011) 0.84
Expression of X-linked inhibitor of apoptosis protein in human prostate cancer specimens with and without neo-adjuvant hormonal therapy. J Cancer Res Clin Oncol (2009) 0.82
The effect of concurrent androgen deprivation and 3D conformal radiotherapy on prostate volume and clinical organ doses during treatment for prostate cancer. Br J Radiol (2009) 0.80
Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer. Drugs (2013) 0.80
Neoadjuvant hormone therapy following treatment with robotic-assisted radical prostatectomy achieved favorable in high-risk prostate cancer. Onco Targets Ther (2014) 0.80
Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy. BMC Urol (2012) 0.80
Leuprorelin depot injection: patient considerations in the management of prostatic cancer. Ther Clin Risk Manag (2008) 0.80
External beam radiation therapy: role of androgen deprivation. World J Urol (2003) 0.79
Hormone therapy in the management of prostate cancer: evidence-based approaches. Ther Adv Urol (2010) 0.79
Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer. Mol Cancer Ther (2014) 0.79
Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer. Adv Ther (2013) 0.79
Short-term versus long-term hormone therapy plus radiotherapy or prostatectomy for prostate cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol (2013) 0.79
Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling. Chin J Cancer (2017) 0.78
Neoadjuvant hormonal deprivation for patients undergoing radical prostatectomy. Asian J Androl (2008) 0.78
Androgen deprivation therapy: a cornerstone in the treatment of advanced prostate cancer. Rev Urol (2004) 0.78
Neoadjuvant Enzalutamide Prior to Prostatectomy. Clin Cancer Res (2016) 0.78
Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis. Int J Clin Oncol (2015) 0.78
Downsizing and prostate cancer. Rev Urol (2004) 0.77
Neoadjuvant hormonal therapy preceding radical prostatectomy for clinically localized prostate cancer: early postoperative complications and biochemical recurrence. Korean J Urol (2011) 0.76
Multimodal approaches to high-risk prostate cancer. Curr Oncol (2010) 0.76
Initial experience with single-agent docetaxel as neoadjuvant therapy in men with locally advanced prostate cancer. Rev Urol (2003) 0.75
Initial experience with single-agent docetaxel as neoadjuvant therapy in men with locally advanced prostate cancer. Rev Urol (2003) 0.75
The Influence of Androgen Deprivation Therapy on Prostate Size and Voiding Symptoms in Prostate Cancer Patients in Korea. Int Neurourol J (2016) 0.75
Neoadjuvant hormonal therapy in men being treated with radiotherapy for localized prostate cancer. Rev Urol (2004) 0.75
Stromal Androgen Receptor in Prostate Cancer Development and Progression. Cancers (Basel) (2017) 0.75
Therapeutic strategies for localized and locally advanced prostate cancer: combining androgen suppression with definitive local therapy. Rev Urol (2003) 0.75
The Effects of Enzalutamide Monotherapy on Multiparametric 3T MR Imaging in Prostate Cancer. Urol Case Rep (2016) 0.75
Reduction in PSA messenger-RNA expression and clinical recurrence in patients with prostatic cancer undergoing neoadjuvant therapy before radical prostatectomy. J Transl Med (2004) 0.75
Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression. J Contemp Brachytherapy (2016) 0.75
Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis. EMBO Mol Med (2016) 0.75
Detection of pelvic lymph node micrometastasis by real-time reverse transcriptase polymerase chain reaction in prostate cancer patients after hormonal therapy. J Cancer Res Clin Oncol (2013) 0.75
Results of conservative management of clinically localized prostate cancer. N Engl J Med (1994) 5.04
The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol (2005) 3.56
Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med (1998) 2.85
Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst (2001) 2.82
Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer (2007) 2.62
Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer (1993) 2.56
Designing Endocrine Disruption Out of the Next Generation of Chemicals. Green Chem (2013) 2.47
Malignant breast masses detected only by ultrasound. A retrospective review. Cancer (1995) 2.41
National survey of UK psychiatrists' attitudes to euthanasia. Lancet (1998) 2.27
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol (2007) 2.24
Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. Euro Surveill (2005) 2.20
Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS (2000) 2.14
Genotyping of Helicobacter pylori isolates by sequencing of PCR products and comparison with the RAPD technique. Res Microbiol (1996) 2.11
Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res (1990) 2.07
Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity (1998) 1.96
A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol (2000) 1.90
Burkholderia pseudomallei virulence: definition, stability and association with clonality. Microbes Infect (2001) 1.90
Prostate cancer: 1. The descriptive epidemiology in Canada. CMAJ (1998) 1.85
A 2-year study of Helicobacter pylori in children. J Clin Microbiol (1994) 1.80
Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract (2013) 1.71
Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res (1998) 1.70
Antifungal susceptibility testing of dermatophytes: establishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates. J Clin Microbiol (2000) 1.68
O-acetylated peptidoglycan: its occurrence, pathobiological significance, and biosynthesis. Can J Microbiol (1992) 1.65
Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol (1996) 1.61
Intermittent endocrine therapy for advanced prostate cancer. Cancer (1986) 1.60
Paratesticular sarcoma: failure patterns after definitive local therapy. J Urol (1999) 1.59
Quality of referral letters. Lancet (2002) 1.58
Use of the internet for self-education by patients with prostate cancer. Urology (2001) 1.57
The role of cisapride in the treatment of pediatric gastroesophageal reflux. The European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr (1999) 1.56
Small-bowel bacterial overgrowth in children with chronic diarrhea, abdominal pain, or both. J Pediatr (1996) 1.52
Allergy to extensively hydrolyzed cow milk proteins in infants: identification and treatment with an amino acid-based formula. J Pediatr (1997) 1.50
Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer (2005) 1.49
Delayed hypersensitivity and systemic arthralgia following transurethral collagen injection for stress urinary incontinence. J Urol (1998) 1.48
Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone. Andrologia (2008) 1.48
Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients. Br J Cancer (2006) 1.47
Duodenogastric reflux in children: measurement of phospholipids and trypsin in gastric content. J Pediatr Gastroenterol Nutr (1990) 1.44
Sleep effects of a 24-h versus a 16-h nicotine patch: a polysomnographic study during smoking cessation. Sleep Med (2006) 1.44
Management of stage II seminoma. J Clin Oncol (1998) 1.43
The atopy patch tests for detection of cow's milk allergy with digestive symptoms. J Pediatr (2003) 1.42
[Feeding of infants based on age. Practice guidelines]. Arch Pediatr (2003) 1.40
Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol (2003) 1.40
Referrals, Wait Times and Diagnoses at an Urgent Neurology Clinic over 10 Years. Can J Neurol Sci (2014) 1.39
Chromium and cobalt ion release following the Durom high carbon content, forged metal-on-metal surface replacement of the hip. J Bone Joint Surg Br (2007) 1.38
Sodium cromoglycate in childhood asthma. Thorax (2001) 1.32
The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. CMAJ (2000) 1.30
NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU Int (2003) 1.28
Characteristics of human basophil sulfidopeptide leukotriene release: releasability defined as the ability of the basophil to respond to dimeric cross-links. J Immunol (1986) 1.28
Current concepts and issues in the management of regurgitation of infants: a reappraisal. Management guidelines from a working party. Acta Paediatr (1996) 1.27
Mononuclear cells from infants allergic to cow's milk secrete tumor necrosis factor alpha, altering intestinal function. Gastroenterology (1994) 1.27
2q23.1 microdeletion identified by array comparative genomic hybridisation: an emerging phenotype with Angelman-like features? J Med Genet (2008) 1.25
Disseminated intravascular coagulation in carcinoma of prostate: role of estrogen therapy. Urology (1983) 1.25
Patients' preferences for communicating a prostate cancer diagnosis and participating in medical decision-making. BJU Int (2004) 1.25
High levels of resistance to metronidazole and clarithromycin in Helicobacter pylori strains in children. J Clin Microbiol (2001) 1.25
A demonstration pilot trial for colorectal cancer screening in the United Kingdom: a new concept in the introduction of healthcare strategies. J Med Screen (2001) 1.25
Intraventricular flow during isovolumic relaxation: description and characterization by Doppler echocardiography. J Am Coll Cardiol (1987) 1.25
Molecular effects of novel mutations in Hesx1/HESX1 associated with human pituitary disorders. Development (2001) 1.23
Tinea capitis in Cleveland: survey of elementary school students. J Am Acad Dermatol (2003) 1.23
Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines. Prostate Cancer Prostatic Dis (2006) 1.21
Mutations in the cationic trypsinogen gene and evidence for genetic heterogeneity in hereditary pancreatitis. J Med Genet (1999) 1.20
The natural history of small renal masses. J Urol (2000) 1.19
Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. Mol Urol (2000) 1.17
Mutations of the p53 gene do not occur in testis cancer. Cancer Res (1993) 1.17
Omeprazole combined with amoxicillin and clarithromycin in the eradication of Helicobacter pylori in children with gastritis: A prospective randomized double-blind trial. J Pediatr (2001) 1.16
Structural features and biochemical properties of TNF-alpha converting enzyme (TACE). J Neuroimmunol (1997) 1.16
Decisional regret and quality of life after participating in medical decision-making for early-stage prostate cancer. BJU Int (2003) 1.16
Catalysis and specificity in enzymatic glycoside hydrolysis: a 2,5B conformation for the glycosyl-enzyme intermediate revealed by the structure of the Bacillus agaradhaerens family 11 xylanase. Chem Biol (1999) 1.15
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J Urol (1989) 1.15
Serum is more suitable than whole blood for diagnosis of systemic candidiasis by nested PCR. J Clin Microbiol (1999) 1.15
Allergic reactions in the community: a questionnaire survey of members of the anaphylaxis campaign. Clin Exp Allergy (2005) 1.14
Multifaceted intervention to decrease the rate of severe postpartum haemorrhage: the PITHAGORE6 cluster-randomised controlled trial. BJOG (2010) 1.14
Current management of castrate-resistant prostate cancer. Curr Oncol (2010) 1.14
[Absence of effect of cisapride on heart rate]. Presse Med (1991) 1.13
Solution structure and mutagenesis of the caspase recruitment domain (CARD) from Apaf-1. Cell Death Differ (1999) 1.13
A novel polymorphic genetic locus in members of the Mycobacterium tuberculosis complex. Microbiology (1999) 1.13
Incidence of leukaemia and other cancers in birth and schools cohorts in the Dounreay area. BMJ (1992) 1.12
Diet, androgens, oxidative stress and prostate cancer susceptibility. Cancer Metastasis Rev (1999) 1.12
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res (2011) 1.11
Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology (1996) 1.10
Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. Prostate Cancer Prostatic Dis (2012) 1.09
CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group. Urology (1999) 1.09
Inhaled sodium cromoglycate in children with asthma. Thorax (2002) 1.08
In vivo release of inflammatory mediators by hyperosmolar solutions. Am Rev Respir Dis (1988) 1.08
Pyogenic granuloma recurring with multiple satellites. A report of 11 cases. Br J Dermatol (1968) 1.08
Transurethral resection of prostatic abscess under sonographic guidance. Urology (1991) 1.08
Metastatic cutaneous Crohn's disease in a child. J Pediatr Gastroenterol Nutr (1998) 1.08
Rotavirus induces alpha-interferon release in children with gastroenteritis. J Pediatr Gastroenterol Nutr (1993) 1.07
Slow cooperative folding of a small globular protein HPr. Biochemistry (1998) 1.07
Predictors of pathological stage before neoadjuvant androgen withdrawal therapy and radical prostatectomy. The Canadian Urologic Oncology Group. J Urol (1998) 1.07
Reduced penetrance alleles for Huntington's disease: a multi-centre direct observational study. J Med Genet (2007) 1.07
Oral food challenge in children: an expert review. Eur Ann Allergy Clin Immunol (2009) 1.06
Adaptive immunity in melioidosis: a possible role for T cells in determining outcome of infection with Burkholderia pseudomallei. Clin Immunol (2004) 1.05